REG - SkinBioTherapeutics - Directorate Change

SkinbiotherapeuticsAnnouncement

18/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220118:nRSR7377Ya&default-theme=true

RNS Number : 7377Y  SkinBioTherapeutics PLC  18 January 2022

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Searches commence for full time CFO and for new non-executive director

with ecommerce and digital marketing background

 

18(th) January 2022 - SkinBioTherapeutics plc (AIM: SBTX), a life science
business focused on skin health, announces that a process has been initiated
to recruit a full time Chief Financial Officer. The Company is also seeking a
new non-executive director to provide further board level support on ecommerce
and social media strategy and overall consumer trends.

Chief Financial Officer

Doug Quinn has acted as SkinBioTherapeutics' part-time CFO since the Company's
IPO in 2017. The past seven years have seen fast growth by the Company, from
its initial focus on research and development to a commercial business with
five distinct pillars for growth. Following this period of rapid growth and
significant progress, and with the launch of its first product in 2021, the
role of CFO has become increasingly demanding. Doug and the rest of the Board
are of the opinion that the role is now best served as a full-time position
and from the Company's offices in Newcastle upon Tyne. Unable to make this
commitment, Doug has decided to step down from his role and board position.

The Company is starting a process looking for a full time CFO with listed
experience and sector experience relevant to the future direction of the
business.  The aim is for a new CFO to be appointed in early Q2 2022 to
ensure an orderly handover.

Doug has agreed to a 12 month lock-in with respect to his share options, all
of which are vested and represent 1.7% of the issued share capital.

Non-Executive Director

SkinBioTherapeutics is also seeking a new non-executive board member. Given
sales and marketing activities in the health and beauty fields are heavily
influenced by digital practices, and, given the Company's increasing ecommerce
platform and digital presence, the aim is to broaden this type of experience
at Board level. The right candidate would ideally have a deep knowledge of
ecommerce, with experience of digital sales and marketing and consumer trends.
 

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"Doug has been a mainstay of SkinBioTherapeutics since before the IPO and
during the Company's rapid growth to its current position with a product on
the market, and a pipeline of other development programmes coming through. He
has achieved all this whilst managing another CFO role. We are therefore
extremely grateful to him for his service and dedication to the Company and
wish him well.

"With Doug's help, we will be seeking a new full-time CFO who can guide the
Company through its next phase of development, moving from a single product
Company to one with multiple commercial arms and additional partnerships with
industry."

Doug Quinn, CFO added:

 

"The evolution of SkinBioTherapeutics from a private R&D Company to a
public, commercial one has been an exciting journey. I am looking forward to
helping my successor find their feet and wish the SkinBioTherapeutics team the
best of luck for the future."

Martin Hunt added:

"There has been an exponential rise in online consumerism, not just as a
result of the pandemic. Therefore, we intend to bring in further experience to
the Board in this area, to support the team around AxisBiotix and in time, new
products in the pipeline."

CVs for either position should be sent to skinbiotix@edwardreed.co.uk
(file:///C:/Users/stuartj.ashman/Library/Containers/com.apple.mail/Data/Library/Mail%20Downloads/16FD429E-05B9-4595-8464-DC6B5A6BF169/skinbiotix@edwardreed.co.uk)

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                 Tel: +44 (0) 161 468 2760

 Stuart J. Ashman, CEO

 Doug Quinn, CFO
 Cenkos Securities Plc (Nominated Adviser & Broker)      Tel: +44 (0) 20 7397 8900

 Giles Balleny, Max Gould (Corporate Finance)

 Michael Johnson, Dale Bellis (Sales)
 Instinctif Partners (financial press)                   Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Nathan Billis                    SkinBio@instinctif.com (mailto:SkinBio@instinctif.com)

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis was launched on 29 October - World
Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For
more information, visit: www.skinbiotix.com (http://www.skinbiotix.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZGMMLNGGZZM